OncTimes Talk: Tumor-Agnostic Classifier & Screener Aids Targeted Drug Development
Description
A tumor-agnostic classifier and screening tool was announced at ESMO Congress 2024 in Barcelona. It was created to make it easier and quicker to develop new drugs that have specific molecular targets, and thus have potential anti-cancer efficacy irrespective of tumor type or location.
The ESMO Tumour-Agnostic Classifier and Screener was the result of work by a multidisciplinary team of international experts led by the ESMO Precision Medicine Working Group. At the conference, Benedikt Westphalen, MD, a medical oncologist and molecular biologist who is Head of the Precision Oncology Program at the University of Munich in Germany, talked about the details with Oncology Times correspondent Peter Goodwin.
Episode: http://otbroadcastsarchives.ovid.libsynpro.com/tumor-agnostic-classifier-screener-aids-targeted-drug-development
Podcast: http://journals.lww.com/oncology-times
United States
